New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
05:55 EDTPFE, PFE, SHPG, SHPG, AZN, AZN, BMY, BMY, TEVA, TEVA, INCY, INCY, RHHBY, RHHBYCBI to host a conference
12th Annual Bio/Pharmaceutical Contact Centers Conference is being held in Philadelphia on January 23-24.
News For PFE;SHPG;AZN;BMY;TEVA;INCY;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 7, 2014
13:06 EDTBMYBMY announces positive results in Phase 1b trial evaluating Opdivo
Subscribe for More Information
December 5, 2014
16:40 EDTINCYDiplomat Pharmacy: FDA approves expanded indication of Jakafi
Subscribe for More Information
13:41 EDTSHPGShire to host research and development day with a conference call hookup
Research and Development meeting to be held in New York on December 10 at 8 am. Webcast Link
11:33 EDTRHHBYGenentech to present clinical data at ASH
Subscribe for More Information
10:22 EDTPFE, BMYBristol-Myers call activity attributed to takeover speculation
Subscribe for More Information
10:05 EDTPFE, BMYBristol-Myers jumps 2% amid talk of potential Pfizer bid
Shares of Bristol-Myers (BMY) are up in early trading amid chatter of a potential takeover bid from Pfizer (PFE). The stock is up $1.26 to $60.15. Bristol's market capitalization stands around $99B, less than twice that of Pfizer's $200B. A Jefferies analyst last week called Mylan (MYL) the most likely takeover target for Pfizer. Pfizer is "highly motivated" to buy a foreign company using its overseas cash and Mylan looks like the most likely target, Jefferies analyst Jeffrey Holford wrote.
09:56 EDTBMY, PFERumor: Bristol-Myers strength attributed to takeover speculation
Subscribe for More Information
09:49 EDTAZNUBS European pharmaceuticals analysts holds analyst/industry conference call
Subscribe for More Information
09:49 EDTINCYIncyte polycythemia vera approval another upside driver, says UBS
Subscribe for More Information
07:54 EDTTEVALannett names Michael Bogda as president, effective December 1
Subscribe for More Information
07:16 EDTINCYFDA PDUFA Date for Incyte's Jakafi (Ruxolitinib) is December 5, 2014
Subscribe for More Information
December 4, 2014
14:49 EDTSHPGSalix, Shire rise after analyst says merger would be 'attractive'
Subscribe for More Information
10:49 EDTINCYFDA approves Jakafi to treat polycythemia vera
Subscribe for More Information
10:32 EDTTEVATeva receives positive outcomes in Europe for three-times-a-week COPAXONE
Teva Pharmaceutical Industries announced that it has received a positive outcome in the decentralized procedure for its new, three-times-a-week COPAXONE 40 mg/ml formulation for the treatment of adults with relapsing forms of multiple sclerosis RMS. The outcome follows a Positive Assessment Report from the United Kingdom, the Reference Member State’s Medicines and Healthcare Products Regulatory Agency, and all Concerned Member States in Europe who were involved in the procedure. Granting of national authorizations will happen in the near future. The three-times-a-week COPAXONE 40 mg/ml formulation will allow for an improved, less-frequent, subcutaneous dosing regimen for adults with RMS. The new formulation reduces the total number of injections by almost 60%, while maintaining the known benefits of once daily COPAXONE 20 mg/ml. “We welcome the opportunity to make COPAXONE 40 mg/ml available to patients with RMS in Europe,” said Rob Koremans, MD, President and CEO of Global Specialty Medicines at Teva. “Three-times-a-week COPAXONE 40 mg/ml will be available in Europe as early as the first quarter of 2015 with expected launches in Germany, Netherlands and Denmark. Launches in other EU countries are expected throughout 2015.”
08:45 EDTAZN, PFEAbbVie price target raised to $80 from $72 at Jefferies
Jefferies raised its price target for AbbVie shares to $80 while calling the company one of its top five global pharma picks for 2015. The firm's top U.S. pick is Pfizer (PFE) and its top Europe pick is Novartis (NVS). Bayer (BAYRY) and AstraZeneca (AZN) round out the top five. Jefferies thinks AbbVie's "strong momentum" will continue into the first half of 2015 and keeps a Buy rating on the name.
05:30 EDTTEVACTI BioPharma receives $15M payment from Teva for TRISENOX
Subscribe for More Information
December 3, 2014
19:11 EDTAZN, SHPGAstraZeneca, Shire interested in Ariad, Daily Mail reports
Ariad (ARIA) is trading higher on speculation that both AstraZeneca (AZN) and Shire (SHPG) are interested in the company with the possibility of an ensuing auction, according to the Daily Mail, which added that analysts see an acquisition price for Ariad of more than $20 per share. Reference Link
17:12 EDTPFEPfizer reports positive results from PROFILE 1014 study
Subscribe for More Information
16:42 EDTPFEDiplomat chosen as limited-distribution pharmacy partner by Pfizer
Subscribe for More Information
07:16 EDTPFEFood & Drug Law Institute to hold a conference
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use